| pubmed-article:1533753 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C0014939 | lld:lifeskim |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C0065864 | lld:lifeskim |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:1533753 | lifeskim:mentions | umls-concept:C1511636 | lld:lifeskim |
| pubmed-article:1533753 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1533753 | pubmed:dateCreated | 1992-6-5 | lld:pubmed |
| pubmed-article:1533753 | pubmed:abstractText | Previous studies have shown that human breast cancer cells (MCF-7) show an increased response to a number of cytotoxic drugs after 48 h pretreatment with medroxyprogesterone acetate (MPA). As there is evidence that MPA can influence membrane fluidity, we have examined the effect of pre-treatment with MPA on the uptake of methotrexate (MTX) and vincristine (VCR) by MCF-7 cells. The effect of pre-treatment with oestrogen on cytotoxic drug uptake was also examined. After 48 h pre-treatment with MPA (40 or 160 nmol/L), the uptake of MTX was significantly reduced by 14%-44%. Uptake of VCR was also reduced (10%-16%) after pre-treatment of cells with MPA but to a lesser degree than detected for MTX. Pre-treatment with ethinyloestradiol increased the uptake of MTX by up to 45% but enhanced uptake was only detected in cells after exposure to MTX for 1 h. While the results from this study show that oestrogens or MPA can alter the uptake of cytotoxic drugs by MCF-7 breast cancer cells, it is not clear how the MPA dependent decrease in drug uptake enhances the response of MCF-7 to such drugs previously reported. | lld:pubmed |
| pubmed-article:1533753 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1533753 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1533753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1533753 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1533753 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:1533753 | pubmed:author | pubmed-author:ReesM WMW | lld:pubmed |
| pubmed-article:1533753 | pubmed:author | pubmed-author:SOALS GSG | lld:pubmed |
| pubmed-article:1533753 | pubmed:author | pubmed-author:GhilchikM WMW | lld:pubmed |
| pubmed-article:1533753 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1533753 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:1533753 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1533753 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1533753 | pubmed:pagination | 533-6 | lld:pubmed |
| pubmed-article:1533753 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:meshHeading | pubmed-meshheading:1533753-... | lld:pubmed |
| pubmed-article:1533753 | pubmed:articleTitle | The effect of oestrogens and medroxyprogesterone acetate on the uptake of cytotoxic drugs by MCF-7 breast cancer cells. | lld:pubmed |
| pubmed-article:1533753 | pubmed:affiliation | Unit of Metabolic Medicine, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, U.K. | lld:pubmed |
| pubmed-article:1533753 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1533753 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
